- Home
- ACRV vs BWAY Comparison
ACRV vs BWAY Comparison
Compare ACRV & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- BWAY
- Stock Information
- Founded
- ACRV 2018
- BWAY 2003
- Country
- ACRV United States
- BWAY Israel
- Employees
- ACRV N/A
- BWAY N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- BWAY Medical/Dental Instruments
- Sector
- ACRV Health Care
- BWAY Health Care
- Exchange
- ACRV Nasdaq
- BWAY Nasdaq
- Market Cap
- ACRV 170.3M
- BWAY 177.4M
- IPO Year
- ACRV 2022
- BWAY 2019
- Fundamental
- Price
- ACRV $5.65
- BWAY $11.05
- Analyst Decision
- ACRV Strong Buy
- BWAY Strong Buy
- Analyst Count
- ACRV 5
- BWAY 3
- Target Price
- ACRV $22.40
- BWAY $13.17
- AVG Volume (30 Days)
- ACRV 50.9K
- BWAY 46.6K
- Earning Date
- ACRV 11-13-2024
- BWAY 03-05-2025
- Dividend Yield
- ACRV N/A
- BWAY N/A
- EPS Growth
- ACRV N/A
- BWAY N/A
- EPS
- ACRV N/A
- BWAY 0.04
- Revenue
- ACRV N/A
- BWAY $38,631,000.00
- Revenue This Year
- ACRV N/A
- BWAY $388.82
- Revenue Next Year
- ACRV N/A
- BWAY $18.70
- P/E Ratio
- ACRV N/A
- BWAY $128.97
- Revenue Growth
- ACRV N/A
- BWAY 34.19
- 52 Week Low
- ACRV $3.19
- BWAY $4.61
- 52 Week High
- ACRV $11.90
- BWAY $11.08
- Technical
- Relative Strength Index (RSI)
- ACRV 41.71
- BWAY 71.27
- Support Level
- ACRV $5.36
- BWAY $10.08
- Resistance Level
- ACRV $6.00
- BWAY $9.75
- Average True Range (ATR)
- ACRV 0.52
- BWAY 0.35
- MACD
- ACRV -0.01
- BWAY 0.16
- Stochastic Oscillator
- ACRV 17.74
- BWAY 98.08
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.